At Investor Meeting, Spotlight is on Bristol-Myers CEO-Designate Lamberto Andreotti --and Pipeline
This article was originally published in The Pink Sheet Daily
Executive Summary
Five new medicines, including a melanoma treatment, are projected to be launched by 2012 to replace sales that will be lost to generics
You may also be interested in...
For Bristol, Onglyza Disappoints And Health Care Reform Takes A Toll
The new health care reform statute will have a significant impact on Bristol-Myers Squibb's sales in 2010 and 2011, the company said during a first quarter sales and earnings call April 29 in which the drug maker announced it is revising earnings guidance for the year as a result
For Bristol, Onglyza Disappoints And Health Care Reform Takes A Toll
The new health care reform statute will have a significant impact on Bristol-Myers Squibb's sales in 2010 and 2011, the company said during a first quarter sales and earnings call April 29 in which the drug maker announced it is revising earnings guidance for the year as a result
For BMS, Onglyza Disappoints And Health Care Reform Takes A Toll
The health care reform law, which will lower Bristol-Myers Squibb's sales by $350 million to $400 million this year, led the firm to revise earnings guidance.